Spero Therapeutics (SPRO) EPS (Weighted Average and Diluted) (2021 - 2026)
Spero Therapeutics (SPRO) reported EPS (Weighted Average and Diluted) of -$0.13 for Q1 2026, up 48.0% on a YoY basis from -$0.09 in Q1 2025, and down 123.21% quarter-over-quarter from $0.56 in Q4 2025.
Spero Therapeutics (SPRO) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Spero Therapeutics has reported EPS (Weighted Average and Diluted) for 6 years, with the latest figure at -$0.13 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 48.0% year-over-year to -$0.13; the trailing twelve-month figure through Mar 2026 stood at $0.27 (up 121.09% YoY), and the FY2025 full-year result was $0.15, up 111.81% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.13, down from $0.56 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $0.97 in Q4 2023, with the low at -$1.01 in Q1 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.12 across 5 years, with a median of -$0.24 in 2024.
- Annual changes were most pronounced in 2024 — EPS (Weighted Average and Diluted) slumped 433.33% — and 2025, when it jumped 247.37%.
- Spero Therapeutics' EPS (Weighted Average and Diluted) stood at $0.93 in 2022, then gained by 4.3% to $0.97 in 2023, then slumped by 139.18% to -$0.38 in 2024, then jumped by 247.37% to $0.56 in 2025, then sank by 123.21% to -$0.13 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.13 (Q1 2026), $0.56 (Q4 2025), and -$0.13 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Spero Therapeutics | 129.74 Mn | 73.61 Mn | - | -0.13 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.13 |
| Dec 31, 2025 | 0.56 |
| Sep 30, 2025 | -0.13 |
| Jun 30, 2025 | -0.03 |
| Mar 31, 2025 | -0.25 |
| Dec 31, 2024 | -0.38 |
| Sep 30, 2024 | -0.32 |
| Jun 30, 2024 | -0.33 |
| Mar 31, 2024 | -0.24 |
| Dec 31, 2023 | 0.97 |
| Sep 30, 2023 | -0.06 |
| Jun 30, 2023 | -0.23 |
| Mar 31, 2023 | -0.25 |
| Dec 31, 2022 | 0.93 |
| Sep 30, 2022 | -0.33 |
| Jun 30, 2022 | -0.87 |
| Mar 31, 2022 | -1.01 |
| Dec 31, 2021 | -0.92 |
| Sep 30, 2021 | -0.70 |
| Jun 30, 2021 | -0.63 |